Open Access<p>Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells</p>
Author(s) -
Inés Velázquez-Quesada,
Angel J. RuizMoreno,
Diana CasiqueAguirre,
Charmina Aguirre-Alvarado,
Fabiola Cortés-Mendoza,
Marisol de la FuenteGranada,
Carlos A. García-Pérez,
Sonia Mayra PérezTapia,
Aliesha GonzálezArenas,
Aldo SeguraCabrera,
Marco A. Velasco-Velázquez
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
ISSN - 1177-8881
DOI - 10.2147/dddt.s247730
Subject(s) - sox2 , chemistry , cd44 , cancer research , viability assay , transactivation , cancer stem cell , stem cell , cell , microbiology and biotechnology , biology , biochemistry , transcription factor , gene
Cancer stem cells (CSCs) drive the initiation, maintenance, and therapy response of breast tumors. CD49f is expressed in breast CSCs and functions in the maintenance of stemness. Thus, blockade of CD49f is a potential therapeutic approach for targeting breast CSCs. In the present study, we aimed to repurpose drugs as CD49f antagonists.